PRECIGEN pipeline
Discovery
by Design
Our pipeline includes several programs leveraging our technologies in core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
AdenoVerse Pipeline
| Product | Platform | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| PRGN-2012 | OTS AdenoVerse | RRP | |||||
| PRGN-2009+pembrolizumab | OTS AdenoVerse | OPSCC | |||||
| PRGN-2009+pembrolizumab | OTS AdenoVerse | R/M Cervical Cancer |
UltraCAR-T Pipeline
| Product | Platform | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| PRGN-3006 | UltraCAR-T | AML, MDS | |||||
| PRGN-3005 | UltraCAR-T | Ovarian Cancer | |||||
| PRGN-3007 | UltraCAR-T | Hematological & Solid Tumors |
Expanded Access Policy
Download PolicyFor physicians seeking pre-approval access to one of our investigational therapies, please review our expanded access policy. For expanded access inquiries, please contact us at expandedaccess@precigen.com.